Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ZymoGenetics ZGEN -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (169)	4/27/2009 12:35:12 PM
From: tuck	Respond to of 210

Thanks for the pointers. I haven't had time to look at the posters yet. I guess, shock of shocks, the PR is a little spun. Nevertheless, VL reduction data is pretty strong. Do you know if there is a standard dose of Ribavirin in these combos and if ZGEN used it here? It would seem that, given lambda's immunological MOA, we might see a better therapeutic window with a lower than usual R dose in the combo. Aside from the VL reduction angle, I'm not going to get too excited one way or the other until we have larger samples to work with. Cheers, Tuck